US/UK/Canada

Share

Quotes

Last year’s increase in sales revenue is a testament to the strength of our technology and the value it delivers to customers. I’m very pleased with the progress we’re seeing. Alongside the positive sales trend, 2025 was a pivotal year in which we established a new management team and developed a five year strategy that positions us in the best possible way for the future.
Jenny Sundqvist, CEO Navinci
Pick a time period -
Tags ( Active)

Navinci to Showcase Omni at EACR 2026

Uppsala, Sweden – June 5, 2026 — Navinci, a leader in spatial interactomics solutions, today announces its participation in the European Association for Cancer Research (EACR) 2026 Congress, taking place from June 8–11, 2026 in Budapest, Hungary.At EACR 2026, Navinci will highlight its growing portfolio of in situ proximity ligation assay (isPLA) based technologies and introduce Omni, a new solution designed to expand the scope of spatial protein analysis. Omni is a multiplex immunoassay platform built on Navinci’s proprietary isPLA technology, enabling spatially resolved detection of

Navinci launches Omni kit – the next generation of spatial interactomics

Uppsala, Sweden – April 29, 2026 — Navinci today announces the launch of Omni, breakthrough fully customized kits designed to transform how scientists study protein function directly in tissue. Omni provides cutting-edge spatial interactomics capabilities, enabling researchers to map protein networks and better understand health, disease progression, and drug mechanisms.Built on Navinci’s proprietary in situ proximity ligation assay (isPLA) technology, Omni allows detection of up to 9 target pairs simultaneously within a single experiment. By using antibody–oligonucleotide pairs that

Navinci to attend AACR and accelerate the pre-launch of new multiplex kit

Uppsala, Sweden – April 15, 2026 - Navinci announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 19-22. At booth #1917, Navinci will highlight its latest advancements, including accelerating the pre-launch of its highly anticipated multiplex kit, Omni, as well as the presentation of two scientific posters developed in collaboration with leading partners.At the event, Navinci will pre-launch its new multiplex kit, Omni, which will be available for shipment starting in May. This technology will enable researchers to

Navinci enters into cross-institutional collaboration for high-throughput spatial interactomics

Uppsala, Sweden – April 7, 2026 – Navinci announced today a new collaborative initiative between Uppsala University, SciLifeLab, the Chemical Biology Consortium Sweden (CBCS), Navinci, and Pixl Bio, which aims to develop a next-generation technology platform for mapping cellular signaling and drug responses at high spatial and molecular resolution.The project Spatial Interactomics with Cell Painting (SIXP) brings together complementary expertise across academia, research infrastructure and industry. Uppsala University researchers contribute leading expertise in molecular interaction biology

Navinci to attend NextGen Omics and Spatial Biology US as silver sponsor and pre-launch new multiplex kit

Uppsala, Sweden – March 27, 2026 – Navinci announced today its attendance at the Oxford Global Event 'NextGen Omics and Spatial Biology US’ taking place in Boston, USA, March 31-April 1.NextGen Omics & Spatial Biology connects thought leaders, researchers, and experts with pharmaceutical & biotech representatives to discuss the latest innovations across the fields of multi-omics. The conference focuses on driving the next generation of multi-omics research, featuring topics on spatial biology, in situ multi-omics, and AI-driven data analysis. At the event, Navinci will pre-launch its new

Navinci reports record sales growth of 72% in 2025

Uppsala, Sweden – March 24, 2026 — Navinci today reported its 2025 annual results. Sales revenue increased by 72%, while operating expenses remained stable, marking a significant step toward the company’s long-term goals.Navinci is a Swedish life science tools company with proprietary technology that helps researchers identify proteins, protein–protein interactions, and post-translational modifications with exceptional precision. The technology provides scientists deeper insight into how cells function in their natural environment, supporting a better understanding of diseases and how drugs

Navinci and Vector Labs Highly Commended at CiteAb Awards 2026

Uppsala, Sweden – March 17, 2026 – Navinci today announced that its collaborative work with Vector Laboratories has been highly commended for the Innovation Award at the CiteAb Awards 2026. This commendation recognizes the impact of the Glysite™ Explorer kit as the first commercially available product to study protein glycosylation, providing a simple approach to understand glycan-protein proximity with a spatial context.The CiteAb Awards celebrate the most significant achievements in life science research tools, and this recognition highlights the strength of the partnership between

Navinci welcomes Kjell Ruth as Chief Commercial Officer

Uppsala, Sweden – February 2, 2026 – Navinci today announced the appointment of Kjell Ruth as Chief Commercial Officer (CCO). In this role, Kjell will lead Navinci’s global commercial strategy and execution, supporting the company’s continued expansion worldwide.Kjell brings broad, cross-functional experience from the biotech and life science industry, spanning business development, sales, marketing, and commercial strategy. He has worked across both high-growth biotech companies and larger global organizations, most recently in Global Marketing at Thermo Fisher Scientific. His experience

Navinci Featured in BioStock

Uppsala, Sweden – October 29, 2025 – Navinci has been featured in an article by BioStock highlighting the company’s unique technology and future ambitions.The article includes an in-depth interview with CEO Jenny Sundqvist, who discusses Navinci’s innovative approach to mapping protein interactions directly in tissue and cell samples - revealing how proteins function together in their native context. The article also highlights Navinci’s legacy, consistent double-digit growth, expanding product portfolio, and ongoing investment in multiplexing and spatial biology technologies. Read

Navinci Launches Naveni® Plex Omni Service Providing Expert-Led Access to Spatial Interactomics

Uppsala, Sweden – 30 September, 2025 – Navinci today announced the launch of the Naveni® Plex Omni Service, a new offering that provides researchers with advanced access to spatial interactomics through the company’s proprietary multiplex in situ proximity ligation assay (misPLA) technology, run by the experts that developed it.Naveni® Plex Omni allows scientists to map protein function and networks in spatial context, to gain deeper insight into basic biology, disease progression, and treatment prediction. The technology enables the simultaneous detection of up to eight protein-protein

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe